12 November 2024 - PHARMAC has decided to fund the medicine empagliflozin for thousands of people with a type of long-term heart failure.

From 1 December 2024, PHARMAC will widen access to empagliflozin for people with a type of chronic heart failure who have reduced ejection fraction. 

Read PHARMAC press release